Presentations on Navigating the Complex Waters in R/R MM - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations on Navigating the Complex Waters in R/R MM

Not a member of My prIME? Join now for instant access.

Improve your understanding of relapsed/refractory multiple myeloma (R/R MM) with expert insights on current and new therapeutic options as well as the adverse event profiles of these therapeutic agents.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Jun 26, 2017

Expiration Date

Jun 26, 2018

Featured Expert

  • Philippe Moreau, MD, University of Nantes, Nantes, France

Featured Topic

Looking back to shore: How did we get to R/R MM?

Featured Expert

  • Meletios Dimopoulos, MD, University of Athens, Athens, Greece

Featured Topic

Wind in our sails: Next-generation therapeutic options in R/R MM

Featured Expert

  • Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Featured Topic

What’s on the near horizon? New targets in R/R MM

Featured Expert

  • Enrique Ocio, MD, PhD, University of Salamanca, Salamanca, Spain

Featured Topic

Avoiding treacherous waters: Balancing efficacy with adversity

Featured Expert

  • Meletios Dimopoulos, MD, University of Athens, Athens, Greece

Featured Topic

prIME Points

This educational activity is designed for hematologists, oncologists, patient advocates, and other healthcare providers involved and/or interested in the management of patients with multiple myeloma (MM).

After successful completion of this educational activity, participants should be able to:

  • Distinguish initial therapeutic strategies for patients who are transplant-eligible versus patients who are transplant-ineligible in the newly diagnosed MM setting
  • Describe the pivotal trials that have led to recent approval of therapies in R/R MM
  • Summarize new targets for therapy in R/R MM currently in late phase clinical trials
  • Identify the common treatment-emergent adverse events associated with different classes of therapeutic agents used in R/R MM

This educational activity is supported by Celgene, Karyopharm Therapeutics, and PharmaMar.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Dimopoulos has disclosed that he has received honoraria or consulting fees from Amgen, Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lonial has disclosed that he has received honoraria or consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moreau has disclosed that he has received honoraria or consulting fees from Amgen, Celgene, Janssen, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ocio has disclosed that he has received grants or research support from Amgen, Array Pharmaceuticals, Celgene, and Mundipharma. He has also received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Mundipharma, Novartis, and Takeda. Dr Ocio has also received consulting fees from Abbvie, Amgen, Array Pharmaceuticals, Celgene, Mundipharma, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.